ICP
NVO

Ironvine Capital Partners’s Novo Nordisk NVO Stock Holding History

Ironvine Capital Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-20,000
Closed -$493K – 78
2018
Q1 		$493K Hold
20,000
– – 0.12% 73
2017
Q4 		$537K Buy
+20,000
New +$509K 0.17% 72

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
SGA
Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return

Ironvine Capital Partners's NVO Position: Q2 2018 in Review

Ironvine Capital Partners sold out of Novo Nordisk (NVO) in Q2 2018, closing a stake of 20,000 shares — an estimated $493K sold.

Ironvine Capital Partners first reported a position in NVO in Q4 2017 and held it in 2 quarters. The position peaked at $537K in Q4 2017. 537 funds tracked by Wall St. Rank hold NVO as of Q2 2018.

  • Ironvine Capital Partners reported no remaining Novo Nordisk position as of Q2 2018 after selling out during the quarter.
  • Ironvine Capital Partners sold 20,000 Novo Nordisk shares in Q2 2018, an estimated $493K.
  • Ironvine Capital Partners first reported a position in Novo Nordisk in Q4 2017 and held it in 2 quarters.
  • Ironvine Capital Partners's Novo Nordisk position peaked at $537K in Q4 2017.
  • 537 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2018.

Based on Ironvine Capital Partners's 13F filing for Q2 2018, filed 26 Jul 2018.